In a study of intraprostatic administration of PSA-targeted vaccine in 21 patients with locally recurrent prostate cancer, patients received a priming vaccine subcutaneously, followed by 3 intraprostatic booster vaccinations at 4-week intervals [79]. The gene discussed is KLK3; the disease is Familial prostate cancer.